News Archive

The National Institute of Allergy and Infectious Diseases (NIAID) recently reissued the funding opportunity announcement (FOA) for the New Innovators Award (PAR-20-259). The first application due date is November 2, 2020. 

 The NIAID New Innovator Award supports a postdoctoral or newly independent Early Stage Investigator of exceptional creativity who proposes novel, original and insightful research concepts with the potential to produce a major impact, test scientific paradigms, or advance key concepts on broad, important problems in biomedical research of priority to NIAID. Applications proposing unexpected convergence of disciplines, new scientific directions, or the use of novel methodologies are encouraged. 

The University System of Maryland has partnered with Labster to provide its virtual laboratory simulations across all USM institutions. The university is working to integrate virtual science labs into its course offerings as the COVID-19 pandemic has limited students’ and instructors’ access to classrooms.

GAITHERSBURG, Md., Aug. 17, 2020 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE: EBS) today announced that the U.S. Food and Drug Administration (FDA) has approved the extension of the shelf life of NARCAN® (naloxone HCl) Nasal Spray from 24 months to 36 months. Narcan Nasal Spray was the first intranasal form of naloxone approved by FDA and Health Canada for the emergency treatment of known or suspected opioid overdose.

GERMANTOWN, Md., Aug. 17, 2020 /PRNewswire/ — Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cellular therapies to improve the lives of patients, today announced that the first patient has been dosed with Precigen’s PRGN-2009, a first-in-class, off-the-shelf (OTS) investigational immunotherapy utilizing the AdenoVerse™ platform designed to activate the immune system to recognize and target HPV+ solid tumors (clinical trial identifier: NCT04432597). HPV-associated cancers represent a significant health burden in indications such as head and neck, cervical, vaginal and anal cancer.

SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Aug. 17, 2020 /PRNewswire/ — United Therapeutics Corporation (Nasdaq: UTHR) today announced that the U.S. Food and Drug Administration (FDA) accepted for review the supplemental New Drug Application (sNDA) for Tyvaso® (treprostinil) Inhalation Solution for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD). United Therapeutics expects the agency’s review to be complete in April 2021.

The 2020 Technology Showcase is going virtual! Reserve the afternoon of September 9th on your calendar for the 2020 Technology Showcase. The 4th annual event will highlight technologies being developed at the NCI and the Frederick National Laboratory for Cancer Research (FNL) to encourage technology licensing and collaborations, startup company formation and the translation of NCI discoveries into solutions to benefit patients.